🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

FDA article outlines the decision-making process and rationale behind removal or narrowing of certain indications for PARP inhibitors in treatment of advanced ovarian cancer - via Journal of Clinical Oncology pubmed.ncbi.nlm.nih.gov/40388682/

Congratulations to FDA Oncology Center Director Richard Pazdur on receiving an Honorary Doctorate in Science degree from @HendrixCollege. Dr. Pazdur has published 800+ articles and led transformative regulatory approaches in cancer treatment. hendrix.edu/Hendrix-Colleg…

Cancer's heterogeneity can limit treatment effectiveness and complicate diagnosis. Researchers are developing new technologies to better characterize and target this complexity. #NationalCancerResearchMonth Learn more: bit.ly/2Myw7rV

A review of #AI and #machinelearning in oncology clinical trials highlights the potential to improve patient recruitment and stratification, trial design and operations, and data management. #ASCO2025 Read more: ascopubs.org/doi/10.1200/ED… #CancerResearch #ClinicalTrials

Then: Limited understanding of cancer risks. Now: We’ve identified preventable causes like tobacco, HPV, and hepatitis B. Vaccines, screenings, and lifestyle changes are helping prevent millions of cases. #NationalCancerResearchMonth Learn more: cancer.gov/about-cancer/c…

Researchers continue working to identify new preventable risk factors, develop more effective interventions, and overcome barriers to prevention strategy implementation across populations. #NationalCancerResearchMonth Learn more: cancer.gov/about-cancer/c…

FDA article outlines the decision-making process and rationale behind removal or narrowing of certain indications for PARP inhibitors in treatment of advanced ovarian cancer - via Journal of Clinical Oncology pubmed.ncbi.nlm.nih.gov/40388682/

🧪 FDA #BenchToBedside video alert! The FDA Oncology Center of Excellence dives into drug development for rare & economically infeasible cancers — with expert voices from across the agency. 🎥 Watch: youtu.be/gmI8z5qtk1M #Oncology #RareDiseases #DrugDevelopment

Large novel FDA analysis suggests adding a CDKI to aromatase inhibitor therapy improved overall survival in patients with HR-positive, HER2-negative advanced or metastatic breast cancer. #ASCO25 meetings.asco.org/abstracts-pres…

FDA article clarifies perspectives on dosage optimization in pediatric oncology and affirms our commitment to expedite development of more effective, better tolerated drugs and biologics for pediatric cancer patients. Clinical Cancer Research aacrjournals.org/clincancerres/…

Large novel FDA analysis suggests adding a CDKI to aromatase inhibitor therapy improved overall survival in patients with HR-positive, HER2-negative advanced or metastatic breast cancer. #ASCO25 meetings.asco.org/abstracts-pres…

A review of #AI and #machinelearning in oncology clinical trials highlights the potential to improve patient recruitment and stratification, trial design and operations, and data management. #ASCO2025 Read more: ascopubs.org/doi/10.1200/ED… #CancerResearch #ClinicalTrials

FDA approves a treatment for metastatic castration-sensitive prostate cancer. fda.gov/drugs/resource…

FDA article clarifies perspectives on dosage optimization in pediatric oncology and affirms our commitment to expedite development of more effective, better tolerated drugs and biologics for pediatric cancer patients. Clinical Cancer Research pubmed.ncbi.nlm.nih.gov/40325515/

June honors cancer survivors—brave souls whose resilience and determination light the path for others. Your strength fuels hope, drives research, and proves that life after cancer is full of possibility. #CancerSurvivorsMonth #SurvivorStrong

FDA approved a treatment for ROS1-positive non-small cell lung cancer. fda.gov/drugs/resource…

FDA approves a treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. fda.gov/drugs/resource…

FDA approves a treatment for adults with resectable locally advanced head and neck squamous cell cancer whose tumors express PD-L1. fda.gov/drugs/resource…

June celebrates cancer survivors and the incredible strength you've shown. Your journeys inspire hope, advance understanding, and remind us all that healing and joy continue beyond diagnosis. #CancerSurvivorsMonth #Hope

🚨 Oct 10, 2025: FDA & The Osteosarcoma Institute workshop on advancing #osteosarcoma drug development. 📍 Washington DC + Virtual ⏰ 9:30am-5pm ET 🎯 Connecting research & regulatory pathways Register by Sept 24 for in-person attendance: fda.gov/news-events/fd… #CancerResearch